Biocon Limited, founded in 1978 by Kiran Mazumdar-Shaw, is a leading biopharmaceutical company headquartered in Bangalore, India. With a global presence, Biocon manufactures generic active pharmaceutical ingredients (APIs) distributed across 120 countries, including key markets like the United States and Europe. Known for its biosimilar insulins, antibodies, and novel biologics, Biocon serves diverse medical needs worldwide. In India, its product range spans metabolics, oncology, immunotherapy, and nephrology, featuring renowned brands like INSUGEN, BASALOG, and CANMAb. Additionally, Biocon’s subsidiary, Syngene International Limited, operates as a contract research and development organization, enhancing the company’s research capabilities.
History of Biocon
Established in 1978 by Kiran Mazumdar with just Rs. 10,000, Biocon swiftly emerged as a global leader in biopharmaceuticals. Notable milestones include pioneering enzyme exports to the US and Europe in 1979 and securing USFDA approval for lovastatin production in 2001. Over the years, strategic collaborations and expansions propelled Biocon’s growth, leading to breakthroughs like the development of human insulin on a Pichia expression system and the launch of BIOMAb EGFR for cancer treatment. Key partnerships with global players like Abbott and Amgen further solidified its position.
In 2021, Biocon Biologics partnered with the Serum Institute of India to commercialize vaccines and biological drugs, amplifying its impact on public health. The acquisition of Viatris’ biosimilar assets in 2022 bolstered its standing in the biosimilars market, underscoring its commitment to advancing healthcare globally. Throughout its journey, Biocon has remained dedicated to innovation, shaping the biopharmaceutical landscape and improving patient outcomes worldwide.
Latest News on Biocon
Biocon recently faced four observations from the US Food and Drug Administration (USFDA) after an inspection of its Bengaluru facility from September 23 to 27, 2024. The company assured that these observations would be addressed within the required timeframe and emphasized that no material impact on its operations is expected. Despite this, Biocon’s stock dropped by 2%, closing at ₹361.5, though the company has seen a notable 44% rise in its stock price so far in 2024.
On a celebratory note, Kiran Mazumdar-Shaw, Biocon’s founder, marked a significant family achievement as her niece’s company, Bicara Therapeutics, made its debut on the Nasdaq, a major milestone for the Boston-based biopharmaceutical firm.
You can buy Biocon shares in India by opening a trading account with a broker. You will need to provide your personal details, such as your PAN number, bank details, and other personal documents. Once the trading account is opened, you can buy Biocon shares using the broker’s online trading platform. You can also buy Biocon shares through a mutual fund or a portfolio management service. Some online platforms to buy shares are Zerodha, Sharekhan, and Upstox.
| When | Maximum Price | Minimum Price |
| October 2024 | 395.05 | 343.53 |
| November 2024 | 410.86 | 357.27 |
| December 2024 | 414.96 | 360.84 |
As we approach October 2024, Biocon’s stock is expected to see a maximum price of ₹395.05 and a minimum price of ₹343.53. Moving into November 2024, the anticipated maximum price for Biocon could reach ₹410.86, while the minimum is likely to hover around ₹357.27. By December 2024, Biocon’s share price is expected to peak at ₹414.96, with a minimum price forecasted at ₹360.84.
| When | Maximum Price | Minimum Price |
| January 2025 | 419.11 | 322.40 |
| February 2025 | 423.35 | 325.65 |
| March 2025 | 432.24 | 332.49 |
| April 2025 | 427.96 | 329.20 |
| May 2025 | 415.49 | 319.61 |
| June 2025 | 434.19 | 333.99 |
| July 2025 | 425.68 | 327.44 |
| August 2025 | 438.84 | 337.57 |
| September 2025 | 444.11 | 341.62 |
| October 2025 | 455.66 | 350.50 |
| November 2025 | 467.05 | 359.27 |
| December 2025 | 488.06 | 375.43 |
As we step into 2025, Biocon’s stock is expected to start with a maximum price of ₹419.11 and a minimum of ₹322.40 in January. Moving forward, the prices are projected to range from ₹432.24 to ₹332.49 in March, and by mid-year in June, the stock may peak at ₹434.19 with a low of ₹333.99. By September, Biocon’s stock could rise to ₹444.11, with a minimum of ₹341.62. As we step into December 2025, the stock is expected to reach its highest point of ₹488.06, with a minimum of ₹375.43.
| When | Maximum Price | Minimum Price |
| January 2026 | 502.71 | 386.70 |
| February 2026 | 490.14 | 377.03 |
| March 2026 | 499.94 | 384.57 |
| April 2026 | 510.14 | 392.42 |
| May 2026 | 505.09 | 388.53 |
| June 2026 | 517.72 | 398.25 |
| July 2026 | 507.57 | 390.44 |
| August 2026 | 523.27 | 402.51 |
| September 2026 | 533.73 | 410.56 |
| October 2026 | 547.61 | 421.24 |
| November 2026 | 561.30 | 431.77 |
| December 2026 | 575.33 | 442.56 |
| When | Maximum Price | Minimum Price |
| January 2027 | 581.09 | 446.99 |
| February 2027 | 595.99 | 458.45 |
| March 2027 | 619.23 | 476.33 |
| April 2027 | 607.09 | 466.99 |
| May 2027 | 589.40 | 453.39 |
| June 2027 | 615.93 | 473.79 |
| July 2027 | 603.85 | 464.50 |
| August 2027 | 622.53 | 478.87 |
| September 2027 | 644.32 | 495.63 |
| October 2027 | 661.07 | 508.51 |
| November 2027 | 677.59 | 521.23 |
| December 2027 | 694.53 | 534.26 |
| When | Maximum Price | Minimum Price |
| January 2028 | 708.42 | 544.94 |
| February 2028 | 726.59 | 558.91 |
| March 2028 | 754.93 | 580.71 |
| April 2028 | 740.12 | 569.33 |
| May 2028 | 718.57 | 552.74 |
| June 2028 | 750.90 | 577.62 |
| July 2028 | 736.18 | 566.29 |
| August 2028 | 758.95 | 583.81 |
| September 2028 | 785.51 | 604.24 |
| October 2028 | 805.93 | 619.95 |
| November 2028 | 826.08 | 635.45 |
| December 2028 | 846.73 | 651.33 |
| When | Maximum Price | Minimum Price |
| January 2029 | 863.67 | 664.36 |
| February 2029 | 885.81 | 681.40 |
| March 2029 | 920.36 | 707.97 |
| April 2029 | 902.31 | 694.09 |
| May 2029 | 876.03 | 673.87 |
| June 2029 | 915.45 | 704.20 |
| July 2029 | 897.50 | 690.39 |
| August 2029 | 925.26 | 711.74 |
| September 2029 | 957.65 | 736.65 |
| October 2029 | 982.55 | 755.80 |
| November 2029 | 1,007.11 | 774.70 |
| December 2029 | 1,032.29 | 794.07 |
| When | Maximum Price | Minimum Price |
| January 2030 | 1,052.93 | 809.95 |
| February 2030 | 1,079.93 | 830.72 |
| March 2030 | 1,122.05 | 863.11 |
| April 2030 | 1,100.05 | 846.19 |
| May 2030 | 1,068.01 | 821.54 |
| June 2030 | 1,116.07 | 858.51 |
| July 2030 | 1,094.18 | 841.68 |
| August 2030 | 1,128.02 | 867.71 |
| September 2030 | 1,167.51 | 898.08 |
| October 2030 | 1,197.86 | 921.43 |
| November 2030 | 1,227.81 | 944.47 |
| December 2030 | 1,258.50 | 968.08 |
In 2030, Biocon’s stock is expected to start in January with a maximum price of ₹1,052.93 and a minimum of ₹809.95. As we move through the year, by March, prices could rise to a maximum of ₹1,122.05 with a minimum of ₹863.11. By mid-year, in June, the stock is projected to reach ₹1,116.07 at its highest and ₹858.51 at its lowest. By September, Biocon’s stock might increase further to ₹1,167.51 with a minimum of ₹898.08. As we approach December 2030, the stock is expected to peak at ₹1,258.50 with a low of ₹968.08.
Biocon Financial Condition: Last 5 Years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 6,300 | 7,143 | 8,184 | 11,174 | 14,756 | 14,766 |
| Expenses + | 4,725 | 5,562 | 6,391 | 8,762 | 11,540 | 11,612 |
| Operating Profit | 1,575 | 1,581 | 1,793 | 2,412 | 3,216 | 3,154 |
| OPM % | 25% | 22% | 22% | 22% | 22% | 21% |
| Other Income + | 228 | 260 | 72 | 18 | 853 | 1,927 |
| Interest | 65 | 58 | 68 | 419 | 974 | 977 |
| Depreciation | 552 | 715 | 814 | 1,113 | 1,569 | 1,616 |
| Profit before tax | 1,186 | 1,068 | 983 | 897 | 1,525 | 2,487 |
| Tax % | 27% | 21% | 22% | 28% | 15% | |
| Net Profit + | 871 | 846 | 772 | 643 | 1,298 | 2,011 |
| EPS in Rs | 6.24 | 6.17 | 5.4 | 3.85 | 8.52 | 13.17 |
| Dividend Payout % | 0% | 0% | 9% | 39% | 6% |
Biocon’s financial performance from March 2020 to March 2024, along with its trailing twelve months (TTM), reflects steady growth in sales and operational profits despite fluctuating profitability.
Sales have increased consistently, rising from ₹6,300 crore in March 2020 to ₹14,756 crore in March 2024, with a slight uptick to ₹14,766 crore in TTM. However, expenses have also escalated, moving from ₹4,725 crore in 2020 to ₹11,540 crore in 2024, leading to a corresponding increase in operating profit, which reached ₹3,216 crore in March 2024, maintaining a 22% operating profit margin (OPM) for most of the period.
The company saw significant volatility in other income, peaking at ₹853 crore in 2024, with an even larger figure of ₹1,927 crore in the TTM. Interest expenses, meanwhile, surged to ₹974 crore in 2024. Depreciation costs have also steadily climbed, from ₹552 crore in 2020 to ₹1,569 crore in 2024.
Profit before tax was ₹1,525 crore in March 2024, with a substantial increase to ₹2,487 crore in the TTM. The tax rate varied, with a drop to 15% in 2024 compared to higher rates in previous years. Net profit nearly doubled from ₹643 crore in March 2023 to ₹1,298 crore in 2024, and further to ₹2,011 crore in TTM. This also resulted in a strong growth in earnings per share (EPS), which rose from ₹3.85 in March 2023 to ₹8.52 in March 2024, and reached ₹13.17 in TTM.
Despite growth, Biocon’s dividend payout ratio has fluctuated, with no payouts in 2020 and 2021, followed by a high of 39% in 2023, though it decreased to 6% in 2024.
Also Read
- BOSCH SHARE PRICE TARGET 2023, 2024, 2025, 2026 TO 2030
- Paytm (One97) Share Price Target 2024, 2025, 2026 to 2030: Should you buy PAYTM?
- Berger Paints India Stock Price Target: 2024, 2025, 2026 to 2030
FAQs
Will Biocon stock price grow in 2024?
Yes, Biocon stock price is expected to grow in 2024. The company’s current share price is around Rs 371, and analysts have estimated that Biocon price will reach ₹414.96 by the end of 2024.
What future is anticipated for Biocon in 2025?
Analysts expect Biocon’s stock price to reach Rs 488.06 by the end of 2025. Biocon focus on innovation and quality is expected to help it maintain its growth in the coming years.
In 2030, Biocon is expected to trade in between ₹809.95 and ₹1,258.50.
Conclusion:
In conclusion, Biocon Limited has demonstrated steady growth in both its stock price and financial performance over recent years. Despite facing operational challenges, including recent USFDA observations, the company continues to expand its global footprint in the biopharmaceutical sector. Biocon’s stock is projected to rise significantly through 2024 to 2030, reflecting confidence in its future growth, with expected peaks in December 2030 at ₹1,258.50. Financially, Biocon has shown consistent increases in sales and operating profit, supported by strategic collaborations and innovative product developments. However, rising expenses and interest costs indicate the need for ongoing financial management to maintain profitability.
What did we learn?
